Memantine is a prescription medication used to treat moderate to severe Alzheimer’s disease. Sold under the brand name Namenda, it works differently from the other main class of Alzheimer’s drugs and is often prescribed alongside them. It does not cure or reverse Alzheimer’s, but it can slow the worsening of symptoms like memory loss, confusion, and difficulty with everyday tasks.
How Memantine Works in the Brain
In a healthy brain, a chemical messenger called glutamate plays an essential role in learning and memory. It activates specific receptors on nerve cells, allowing signals to pass between them. In Alzheimer’s disease, glutamate signaling goes haywire. Too much glutamate floods these receptors, overstimulating nerve cells in a process called excitotoxicity. Over time, this damages and kills neurons, accelerating cognitive decline.
Memantine blocks the channel where excess glutamate does its damage, but it does so in a selective way. It preferentially targets nerve cells that are already abnormally overstimulated while allowing normal glutamate signaling to continue relatively uninterrupted. This selectivity is what makes it useful as a daily medication rather than something that simply numbs brain activity. The net effect is a reduction in the toxic overstimulation that drives nerve cell death, without shutting down the healthy signaling the brain still needs.
Who It Is Prescribed For
Memantine is FDA-approved specifically for moderate to severe Alzheimer’s disease. This distinguishes it from cholinesterase inhibitors (like donepezil), which are typically started in the mild to moderate stages. Many people with advancing Alzheimer’s end up taking both types of medication together. A combination pill containing both memantine and donepezil is available under the brand name Namzaric.
In clinical trials, adding memantine to an existing cholinesterase inhibitor regimen produced measurable cognitive benefits compared to the cholinesterase inhibitor alone. At 24 weeks, patients on the combination scored an average of 2.6 points higher on a cognitive assessment scale, a statistically significant difference. Clinician-rated global impressions of the patients also favored the combination therapy.
What to Realistically Expect
Memantine is not a cure, and it does not stop Alzheimer’s disease from progressing. What it can do is slow the pace of cognitive and functional decline, potentially keeping someone more independent for longer. Some patients and families notice a stabilization of symptoms or a modest improvement in the first months of treatment. Others may not see obvious changes but may be declining more slowly than they would without the medication.
The benefits are typically modest, and they vary from person to person. Memantine tends to help more with daily functioning, behavior, and agitation than with pure memory performance, though effects on cognition are documented. It is generally considered a treatment that preserves quality of life rather than one that dramatically reverses symptoms.
Off-Label Uses
Doctors sometimes prescribe memantine for conditions beyond Alzheimer’s. One of the better-studied off-label uses is vascular dementia, a type of cognitive decline caused by reduced blood flow to the brain. Studies involving roughly 750 patients found a small but real benefit for cognition, behavior, and mood compared to placebo. A network meta-analysis comparing various dementia drugs called memantine the “better comprehensive choice” for vascular cognitive impairment based on its balance of effectiveness and tolerability.
Memantine is also prescribed off-label for obsessive-compulsive disorder (OCD), autism spectrum disorder, and post-traumatic stress disorder, though the evidence for these uses is still being established. There is preliminary evidence suggesting it may help with migraine prevention, but this remains an area of early investigation rather than standard practice. One particularly promising off-label application is protecting cognitive function in cancer patients receiving brain radiation, where a randomized trial showed memantine preserved memory and quality of life significantly better than placebo over 24 weeks.
Dosing and How It Is Started
Memantine comes in two forms: an immediate-release tablet taken twice daily and an extended-release capsule taken once daily. Both versions are started at a low dose and gradually increased over several weeks, a process called titration that helps minimize side effects.
For the extended-release version (Namenda XR), the starting dose is 7 mg once daily. The dose increases by 7 mg each week, as tolerated, up to a target of 28 mg once daily. The immediate-release version follows a similar gradual increase, reaching a maximum of 10 mg twice daily. People with severe kidney impairment typically take a reduced dose, since the kidneys are responsible for clearing memantine from the body. For those patients, the extended-release target is 14 mg once daily instead of 28 mg.
Patients already stabilized on the immediate-release version can switch directly to the extended-release capsule the day after their last tablet dose, without needing to re-titrate.
Side Effects
Memantine is generally well tolerated. In clinical trials involving nearly 1,000 patients on the drug and a similar number on placebo, the rate of people stopping the medication due to side effects was actually slightly lower in the memantine group (10.1%) than in the placebo group (11.5%).
The most common side effects, occurring in at least 5% of patients and more often than with placebo, are dizziness (7% vs. 5% on placebo), headache (6% vs. 3%), confusion (6% vs. 5%), and constipation (5% vs. 3%). Less common effects reported in 2% to 4% of patients include fatigue, back pain, drowsiness, high blood pressure, vomiting, hallucinations, and coughing. Many of these occurred at rates only slightly higher than in people taking a sugar pill, which makes it difficult to know how many are truly caused by the medication versus the underlying disease or normal aging.
Because confusion and hallucinations can also be symptoms of advancing Alzheimer’s itself, it is sometimes hard for families to tell whether these represent a side effect or disease progression. The gradual dose increase at the start of treatment helps identify whether new symptoms are related to the medication.